Viking Therapeutics holds routine 2026 Annual Meeting, elects two directors

Filed May 26, 2026 · Period ending May 19, 2026 · ~1 min read

Key Changes

• low

  Shareholders elected J. Matthew Singleton and S. Kathryn Rouan as Class II directors for three-year terms through 2029. Quorum of 69.1% of outstanding shares represented at virtual meeting.

  Item 5.07 verify on EDGAR →
• low

  Stockholders ratified CBIZ CPAs P.C. as independent auditor for fiscal 2026 with 98% approval (78.4M votes for vs 1.2M against).

  Item 5.07 verify on EDGAR →
• low

  Executive compensation received shareholder approval in advisory vote, consistent with standard annual meeting procedures.

  Item 5.07 verify on EDGAR →